REDEFINE-HFSponsor / Study Title: CPC Clinical Research / RandomizEd Trial to DEtermine the Efficacy and Safety of FINErenone on Morbidity and Mortality Among Heart Failure patients with Left Ventricular Ejection Fraction Greater Than or Equal to 40% ho

REDEFINE HF Andrew Kolodziej, MD ABSTRACT This study will find out whether finerenone (which is the drug we will be investigating in this study) can lower the risk of heart failure and death in patients who are hospitalized with heart failure. Approximately 5200 people are expected to take part in the study. This is a pragmatic, interventional, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the hypothesis that among patients with acute decompensated heart failure (HF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), finerenone will significantly reduce total (first and subsequent) HF events and cardiovascular (CV) death compared with placebo